Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Existing backers participate in NeoVista's $18mm Series D

Executive Summary

Returning shareholders Essex Woodlands, Versant Ventures, SV Life Sciences, Accuitive Medical Ventures, MPM Capital, and the Carlyle Group have provided $18mm in Series D funding to NeoVista, which is in the late stages of developing a beta radiation-delivering device in combination with the anti-VEGF drug Avastin for wet age-related macular degeneration.
Deal Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies